Teva Beats Janssen On Canadian Bortezomib Compensation
Rival To Velcade Held Up By Invalid Patents
Executive Summary
Teva is eligible for compensation due to having been kept off the Canadian bortezomib market by Janssen suing for infringement of two patents that were subsequently found to be obvious.